Generic Onpattro Availability
Last updated on Jun 11, 2025.
Onpattro is a brand name of patisiran, approved by the FDA in the following formulation(s):
ONPATTRO (patisiran sodium - solution;intravenous)
-
Manufacturer: ALNYLAM PHARMS INC
Approval date: August 10, 2018
Strength(s): EQ 10MG BASE/5ML (EQ 2MG BASE/ML) [RLD]
Is there a generic version of Onpattro available?
No. There is currently no therapeutically equivalent version of Onpattro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onpattro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for inhibiting expression of transthyretin
Patent 10,240,152
Issued: March 26, 2019
Inventor(s): Sah Dinah Wen-Yee & Hinkle Gregory & Alvarez Rene & Milstein Stuart & Chen Qingmin
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Patent expiration dates:
- October 20, 2029✓✓✓
- October 20, 2029
-
Methods of treating transthyretin (TTR) mediated amyloidosis
Patent 11,079,379
Issued: August 3, 2021
Inventor(s): Bettencourt Brian
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
Patent expiration dates:
- August 27, 2035✓✓✓
- August 27, 2035
-
Lipid formulations for nucleic acid delivery
Patent 11,141,378
Issued: October 12, 2021
Inventor(s): Yaworski Edward & Lam Kieu & Jeffs Lloyd & Palmer Lorne & MacLachlan Ian
Assignee(s): ARBUTUS BIOPHARMA CORPORATIONThe present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Patent expiration dates:
- April 15, 2029✓
- April 15, 2029
-
Lipid formulations for nucleic acid delivery
Patent 8,058,069
Issued: November 15, 2011
Inventor(s): Yaworski; Edward et al.
Assignee(s): Protiva Biotherapeutics, Inc. (Burnaby, B.C., CA)The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Patent expiration dates:
- April 15, 2029✓
- April 15, 2029
-
Lipid formulation
Patent 8,158,601
Issued: April 17, 2012
Inventor(s): Chen Jianxin & Ansell Steven & Akinc Akin & Dorkin Joseph Robert & Qin Xiaojun & Cantley William & Manoharan Muthiah & Rajeev Kallanthottathil G. & Narayanannair Jayaprakash K. & Jayaraman Muthusamy
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention features a cationic lipid of formula I,
Patent expiration dates:
- November 10, 2030✓✓
- November 10, 2030
-
Compositions and methods for inhibiting expression of transthyretin
Patent 8,168,775
Issued: May 1, 2012
Inventor(s): Sah Dinah Wen-Yee & Hinkle Gregory & Alvarez Rene & Milstein Stuart & Chen Qingmin
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Patent expiration dates:
- August 10, 2032✓✓✓
- August 10, 2032
-
Nuclease resistant double-stranded ribonucleic acid
Patent 8,334,373
Issued: December 18, 2012
Inventor(s): Vornlocher Hans-Peter & Roehl Ingo & Hadwiger Philipp & Zimmermann Tracy Stage & Manoharan Muthiah & Rajeev Kallanthottathil G. & Akinc Akin
Assignee(s): Alnylam Pharmaceuticals, Inc.This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
Patent expiration dates:
- May 27, 2025✓✓
- May 27, 2025
-
Lipid formulations for nucleic acid delivery
Patent 8,492,359
Issued: July 23, 2013
Inventor(s): Yaworski Edward & Lam Kieu & Jeffs Lloyd & Palmer Lorne & MacLachlan Ian
Assignee(s): Protiva Biotherapeutics, Inc.The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Patent expiration dates:
- April 15, 2029✓
- April 15, 2029
-
Lipid containing formulations
Patent 8,642,076
Issued: February 4, 2014
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Akinc Akin & Jayaprakash Narayanannair K. & Jayaraman Muthusamy & Maier Martin
Assignee(s): Tekmira Pharmaceuticals CorporationCompositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
Patent expiration dates:
- October 3, 2027✓
- October 3, 2027
-
Compositions and methods for inhibiting expression of transthyretin
Patent 8,741,866
Issued: June 3, 2014
Inventor(s): Sah Dinah Wen-Yee & Hinkle Gregory & Alvarez Rene & Milstein Stuart & Chen Qingmin
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Patent expiration dates:
- October 20, 2029✓
- October 20, 2029
-
Lipid formulation
Patent 8,802,644
Issued: August 12, 2014
Inventor(s): Chen Jianxin & Ansell Steven & Akinc Akin & Dorkin Joseph Robert & Qin Xiaojun & Cantley William & Manoharan Muthiah & Rajeev Kallanthottathil G. & Narayanannair Jayaprakash K. & Jayaraman Muthusamy
Assignee(s): Tekmira Pharmaceuticals CorporationThe invention features a cationic lipid of formula I,
Patent expiration dates:
- October 21, 2030✓✓
- October 21, 2030
-
Lipid formulations for nucleic acid delivery
Patent 8,822,668
Issued: September 2, 2014
Inventor(s): Yaworski Edward & Lam Kieu & Jeffs Lloyd & Palmer Lorne & MacLachlan Ian
Assignee(s): Protiva Biotherapeutics, Inc.The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Patent expiration dates:
- April 15, 2029✓✓
- April 15, 2029
-
Compositions and methods for inhibiting expression of transthyretin
Patent 9,234,196
Issued: January 12, 2016
Inventor(s): Sah Dinah Wen-Yee & Hinkle Gregory & Alvarez Rene & Milstein Stuart & Chen Qingmin
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Patent expiration dates:
- October 20, 2029✓✓
- October 20, 2029
-
Lipid formulations for nucleic acid delivery
Patent 9,364,435
Issued: June 14, 2016
Inventor(s): Yaworski Edward & Lam Kieu & Jeffs Lloyd & Palmer Lorne & MacLachlan Ian
Assignee(s): PROTIVA BIOTHERAPEUTICS, INC.The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Patent expiration dates:
- April 15, 2029✓✓
- April 15, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 10, 2025 - INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
- January 13, 2026 - INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION
More about Onpattro (patisiran)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Vutrisiran
Vutrisiran (brand name Amvuttra) is used to treat nerve damage associated with hereditary ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
